Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Children can keep full visual perception – the ability to process and understand visual information – after brain surgery for severe epilepsy, according to a study funded by the National Eye Institute (NEI), part of the National Institutes of Health.
A recent study, led by researchers at McGill University, offers an important step in unlocking the mystery of Leber hereditary optic neuropathy’s cause.
Johns Hopkins Medicine researchers report they have created a method of mapping how the central nervous system develops by tracking the genes expressed in cells.
Johns Hopkins Medicine scientists say that new experiments with mouse eye tissues strongly suggest that a longstanding “textbook concept” about the way a mammal’s retina processes light needs a rewrite.
Participants in a phase I/II clinical trial of a new enzyme-based treatment for severe dry eye disease experienced reduced signs of disease and discomfort, according to a paper in Translational Vision Science and Technology.
People with good vision despite having center-involved diabetic macular edema can safely forego immediate treatment of their eye condition as long as they are closely monitored, and treatment begins promptly if vision worsens, according to clinical trial.
Research has shown that people who are born blind or become blind early in life often have a more nuanced sense of hearing, especially when it comes to musical abilities and tracking moving objects in space (imagine crossing a busy road using sound alone)
A research team at Massachusetts Eye and Ear has shown that microglia, the primary immune cells of the central nervous system—including the retina of the eye—serve as “gatekeepers,” or biosensors and facilitators, of neuroinflammation...
In studies with lab-grown human cells and in mice, Johns Hopkins Medicine researchers have found that an experimental drug may be twice as good at fighting vision loss as previously thought.